Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJufar, Alemayehu H-
dc.contributor.authorLankadeva, Yugeesh R-
dc.contributor.authorMay, Clive N-
dc.contributor.authorCochrane, Andrew D-
dc.contributor.authorMarino, Bruno-
dc.contributor.authorBellomo, Rinaldo-
dc.contributor.authorEvans, Roger G-
dc.identifier.citationComprehensive Physiology 2021; 12(1): 2799-2834en
dc.description.abstractCardiac surgery-associated acute kidney injury and brain injury remain common despite ongoing efforts to improve both the equipment and procedures deployed during cardiopulmonary bypass (CPB). The pathophysiology of injury of the kidney and brain during CPB is not completely understood. Nevertheless, renal (particularly in the medulla) and cerebral hypoxia and inflammation likely play critical roles. Multiple practical factors, including depth and mode of anesthesia, hemodilution, pump flow, and arterial pressure can influence oxygenation of the brain and kidney during CPB. Critically, these factors may have differential effects on these two vital organs. Systemic inflammatory pathways are activated during CPB through activation of the complement system, coagulation pathways, leukocytes, and the release of inflammatory cytokines. Local inflammation in the brain and kidney may be aggravated by ischemia (and thus hypoxia) and reperfusion (and thus oxidative stress) and activation of resident and infiltrating inflammatory cells. Various strategies, including manipulating perfusion conditions and administration of pharmacotherapies, could potentially be deployed to avoid or attenuate hypoxia and inflammation during CPB. Regarding manipulating perfusion conditions, based on experimental and clinical data, increasing standard pump flow and arterial pressure during CPB appears to offer the best hope to avoid hypoxia and injury, at least in the kidney. Pharmacological approaches, including use of anti-inflammatory agents such as dexmedetomidine and erythropoietin, have shown promise in preclinical models but have not been adequately tested in human trials. However, evidence for beneficial effects of corticosteroids on renal and neurological outcomes is lacking. © 2021 American Physiological Society. Compr Physiol 11:1-36, 2021.en
dc.titleRenal and Cerebral Hypoxia and Inflammation During Cardiopulmonary Bypass.en
dc.typeJournal Articleen
dc.identifier.journaltitleComprehensive Physiologyen
dc.identifier.affiliationIntensive Care..en
dc.identifier.affiliationThe Florey Institute of Neuroscience and Mental Health..en
dc.identifier.affiliationCardiovascular Disease Program, Biomedicine Discovery Institute and Department of Physiology, Monash University, Melbourne, Victoria, Australia..en
dc.identifier.affiliationDepartment of Critical Care, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Victoria, Australia..en
dc.identifier.affiliationCellsaving and Perfusion Resources, Melbourne, Victoria, Australia..en
dc.identifier.affiliationDepartment of Cardiothoracic Surgery, Monash Health and Department of Surgery (School of Clinical Sciences at Monash Health), Monash University, Melbourne, Victoria, Australia..en
dc.identifier.pubmedid34964119-, Rinaldo
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.openairecristype Care- Analytics Research and Evaluation (DARE) Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Dec 10, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.